Status:
WITHDRAWN
A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborating Sponsors:
Ortho Biotech Clinical Affairs, L.L.C.
Conditions:
Myelodysplastic Syndromes
Anemia
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the effectiveness of PROCRIT (Epoetin alfa) 80,000 Units given once weekly or 80,000 Units given once every two weeks in anemic patients with Low- or Intermedi...
Detailed Description
This is a randomized (patients are assigned to a type of treatment by chance), open-label (both the patient and the physician know what treatment is being given), multi-center study in approximately 1...
Eligibility Criteria
Inclusion
- Diagnosis of Myelodysplastic Syndromes (MDS) via bone marrow aspirate and biopsy according to World Health Organization (WHO) Criteria or French-American-British (FAB) Classification. All WHO and FAB subtypes of MDS are potentially eligible, provided the subject's International Prognostic Scoring System (IPSS) score is Low- or Intermediate-1 \[with the exception of chronic myelomonocytic leukemia (CMML)\]
- Documentation of IPSS score of Low- or Intermediate-1 risk disease (\<= 10% bone marrow blasts), based on bone marrow aspirate, biopsy, and cytogenetics, within 12 weeks prior to study entry
- Baseline hemoglobin (Hb) value of \<10 g/dL \[defined as the average of at least 2 measurements \[(not influenced by red blood cell (RBC) transfusions for at least 1 week) \>= 1 week apart\]. The Hb level prior to the first dose of PROCRIT (Epoetin alfa) cannot be \> 10.5 g/dL.
Exclusion
- No anemia due to factors other than MDS (including hemolysis or gastrointestinal bleeding)
- No proliferative (White Blood Cells (WBC) \>= 12,000/mm3) chronic myelomonocytic leukemia (CMML)
- No history of (within 12 months) deep venous thrombosis \[(DVT), includes proximal and distal\], pulmonary embolism (PE), or other venous thrombosis. Prior superficial thrombophlebitis is not an exclusion criterion
- No history of (within 6 months) cerebrovascular accident \[(CVA), includes ischemic, embolic and hemorrhagic\], transient ischemic attack (TIA), myocardial ischemia \[includes Unstable Angina, Q wave Myocardial Infarction (QwMI) and non-Q wave Myocardial Infarction (NQMI)\], or other arterial thrombosis
- No prior Erythropoietin Receptor Agonist (ERA) treatment within 4 weeks prior to the first study dose
- No prior ERA treatment failure (defined as having shown no Hb response or a Hb response \<1 g/dL after at least 6 weeks of ERA treatment) with minimum dose of Epoetin alfa 40,000 Units/week or Darbepoetin alfa 150 mcg/ week.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00446602
End Date
August 1 2009
Last Update
September 20 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.